2021
DOI: 10.1016/j.jaut.2021.102681
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson & Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after Ad26.COV.2.S vaccination presents later with similar symptoms compared to CVT after administration of ChAdOx1 nCoV-19, albeit with… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
31
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 34 publications
(32 citation statements)
references
References 9 publications
1
31
0
Order By: Relevance
“…They have shown no difference in mortality between the two groups, but patients who received the Vaxzevria vaccine presented earlier after a median of 10 days, 18 which matches the results in the present study. Two out of the three CVT patients in the current study died, and their radiological investigations showed intracranial hemorrhage, while labs showed severe thrombocytopenia.…”
Section: Cvtsupporting
confidence: 91%
“…They have shown no difference in mortality between the two groups, but patients who received the Vaxzevria vaccine presented earlier after a median of 10 days, 18 which matches the results in the present study. Two out of the three CVT patients in the current study died, and their radiological investigations showed intracranial hemorrhage, while labs showed severe thrombocytopenia.…”
Section: Cvtsupporting
confidence: 91%
“…VITT is regarded as a new syndrome associated with preparations of adenoviral vector-based COVID-19 vaccines [ 90 , 92 ]. Recent findings point to a more prominent (1:100,000 cases) presentation after ChadOx1 nCoV-19 vaccination than after Ad.26COV.2.S vaccination, likely related to the composition of the vaccines [ 93 , 94 ]. Both systemic venous and arterial thrombotic complications have been reported.…”
Section: Platelets In Vaccine-induced Thrombosis With Thrombocytopenia (Vitt)mentioning
confidence: 99%
“…Frequently the onset of symptoms was a few days before presentation to hospital. The time window for onset of vaccine-associated CVT may thus be overestimated in studies that have reported the median time from vaccination to hospitalisation to be more than 10 days [ 13 , 14 ].…”
Section: Discussionmentioning
confidence: 99%